Literature DB >> 15164971

Population pharmacokinetics of gentamicin in hospitalized patients receiving once-daily dosing.

Dawei Xuan1, David P Nicolau, Charles H Nightingale.   

Abstract

The purpose of this study was to describe the population pharmacokinetics of gentamicin in a group of 939 adult hospitalized patients receiving once-daily administration of gentamicin and to evaluate the potential influence of patient covariates on gentamicin disposition. Data comprising 1294 serum concentrations from 939 patients, were analyzed using a nonlinear mixed-effect model (NONMEM). The patients had an average age of 55 and an average weight of 70 kg, 431 of the patients were female. The patient covariates including body weight, gender, age, and creatinine clearance (CL(CR)) were analyzed in a stepwise fashion to identify their potential influences on gentamicin pharmacokinetics. The data were best described with a two-compartment model. NONMEM analyses showed that gentamicin clearance (CL, l/h) was linearly correlated with CLcR with proportionality constant: 0.047 (S.E.: 0.0035) x CL(CR) (ml/min). Volume of the central compartment (V1, 1) was linearly related to body weight with proportionality constant: 0.28 (S.E.: 0.021) x body weight (kg). The mean population estimates of CL and V1 were 4.32 l/h and 19.61. respectively. The inter-individual variability in CL and V1 were 29.6 and 5.8%, respectively. Residual errors were 0.23 mg/l and 23.7%. The mean population values of CL and V1 of gentamicin dosed once daily are in agreement with those described by others. This analysis indicates that once-daily dosing (7 mg/kg) of gentamicin should achieve satisfactory concentration in patients with normal renal function although serum concentration monitoring is required to confirm the optimal dosing interval in patients with impaired renal function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164971     DOI: 10.1016/j.ijantimicag.2003.07.010

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Population Pharmacokinetic Analyses for Arbekacin after Administration of ME1100 Inhalation Solution.

Authors:  Elizabeth A Lakota; Nobuo Sato; Tomokazu Koresawa; Kenichiro Kondo; Sujata M Bhavnani; Paul G Ambrose; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

2.  Comparison of four renal function estimation equations for pharmacokinetic modeling of gentamicin in geriatric patients.

Authors:  Nicolas Charhon; Michael N Neely; Laurent Bourguignon; Pascal Maire; Roger W Jelliffe; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2012-01-30       Impact factor: 5.191

3.  Population pharmacokinetics of gentamicin and dosing optimization for infants.

Authors:  Susanna E Medellín-Garibay; Aída Rueda-Naharro; Silvia Peña-Cabia; Benito García; Silvia Romano-Moreno; Emilia Barcia
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

Review 4.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

5.  The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration.

Authors:  Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick
Journal:  Eur J Clin Pharmacol       Date:  2014-02-14       Impact factor: 2.953

6.  Predictive performance of gentamicin dosing nomograms.

Authors:  Jieon Lee; Seonghae Yoon; Donghoon Shin; HyeKyung Han; Hyungmi An; Jongtae Lee; Kyoung Soo Lim; Kyung-Sang Yu; Howard Lee
Journal:  Drug Des Devel Ther       Date:  2014-08-16       Impact factor: 4.162

7.  Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

Review 8.  Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.

Authors:  Caspar J Hodiamont; Annemieke K van den Broek; Suzanne L de Vroom; Jan M Prins; Ron A A Mathôt; Reinier M van Hest
Journal:  Clin Pharmacokinet       Date:  2022-06-27       Impact factor: 5.577

9.  Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose.

Authors:  Chenyan Zhao; Anna Chirkova; Staffan Rosenborg; Rodrigo Palma Villar; Johan Lindberg; Sven N Hobbie; Lena E Friberg
Journal:  J Antimicrob Chemother       Date:  2022-09-30       Impact factor: 5.758

10.  Model-Informed Drug Development for Antimicrobials: Translational PK and PK/PD Modeling to Predict an Efficacious Human Dose for Apramycin.

Authors:  Tomás Sou; Jon Hansen; Edgars Liepinsh; Maria Backlund; Onur Ercan; Solveiga Grinberga; Sha Cao; Paraskevi Giachou; Anna Petersson; Magdalena Tomczak; Malgorzata Urbas; Dorota Zabicka; Carina Vingsbo Lundberg; Diarmaid Hughes; Sven N Hobbie; Lena E Friberg
Journal:  Clin Pharmacol Ther       Date:  2020-11-28       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.